{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-008733","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.583926+00:00","generated_at":"2026-05-15T09:52:20.844389+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Genprex announces positive preclinical data for Reqorsa at AACR 2026","bullets":["TROP2 and PTEN identified as potential biomarkers of primary resistance to TUSC2 gene therapy; 50% of NSCLC cell lines resistant.","Reqorsa plus alectinib achieved 79% tumor shrinkage in ALK+ sensitive model, 23% improvement vs alectinib alone.","In alectinib-resistant model, Reqorsa + alectinib produced synergistic tumor reduction and improved overall survival (p=0.0001).","TUSC2 restoration enhanced NK cell cytotoxicity; 67% of Tusc2 KO mice and 33% of wild-type mice achieved complete tumor regression.","Findings support progression toward clinical trials for ALK+ NSCLC and biomarker-guided patient selection."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-008733","json":"https://secwatch.observer/filing/0001437749-26-008733.json","markdown":"https://secwatch.observer/filing/0001437749-26-008733.md","text":"https://secwatch.observer/filing/0001437749-26-008733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926008733/0001437749-26-008733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926008733/gnpx20260316_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:52:20.844389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}